Catalog No.
EHG01302
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Lys44-Ala750
Predicted molecular weight
82.42 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q04609
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Glutamate carboxypeptidase 2, 3.4.17.21, Cell growth-inhibiting gene 27 protein, Folate hydrolase 1, Folylpoly-gamma-glutamate carboxypeptidase, FGCP, Glutamate carboxypeptidase II, GCPII, Membrane glutamate carboxypeptidase, mGCP, N-acetylated-alpha-linked acidic dipeptidase I, NAALADase I, Prostate-specific membrane antigen, PSM, PSMA, Pteroylpoly-gamma-glutamate carboxypeptidase, FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27
Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer., PMID:40503743
Prostate-Specific Membrane Antigen PET/Computed Tomography: Pearls and Pitfalls., PMID:40500101
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging., PMID:40493195
Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11., PMID:40481129
Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer., PMID:40469300
Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer : Joint statement of the Austrian Society of Nuclear Medicine and Theranostics and the Austrian Society of Urology and Andrology., PMID:40464929
PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications., PMID:40459584
The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions., PMID:40448740
Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era., PMID:40428882
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers., PMID:40427518
Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI., PMID:40425348
Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas., PMID:40420236
Estimating the Optimal Time to Perform a Positron Emission Tomography With Prostate-Specific Membrane Antigen in Prostatectomized Patients, Based on Data From Clinical Practice., PMID:40401727
Bounce effect or local recurrence after low-dose-rate brachytherapy of the prostate? When prostate-specific membrane antigen positron emission tomography-computed tomography is false positive: a case report., PMID:40394696
A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma., PMID:40379702
Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment., PMID:40377421
Dysregulated calcium signaling in the aged macaque entorhinal cortex associated with tau hyperphosphorylation., PMID:40365352
Development of Novel Radiotheranostic Ligand with Positively Charged Unit Targeting Prostate-Specific Membrane Antigen., PMID:40358362
Advanced Precision Dual Photothermal and Photodynamic Therapy for Prostate Cancer Using PSMA-ICG-Conjugated Gold Nanorods., PMID:40340375
Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis., PMID:40325961
Diagnostic Accuracy of PSMA-targeted 18F-Florastamin PET/CT in Intermediate-risk Patients With Suspected Prostate Cancer., PMID:40320630
PSMA PET/CT for prostate cancer diagnosis: current applications and future directions., PMID:40319443
Development of a PSMA and EphA2 dual-receptor-activated fluorescent probe for wash-free prostate cancer cell imaging., PMID:40315731
PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer., PMID:40312858
PSMA-Targeted Biopsy With Fusion Guidance for Detecting Clinically Significant Prostate Cancer in Men With Negative MRI-Feasibility and Diagnostic Performance of a Pilot Single-Center Prospective Study., PMID:40312220
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future., PMID:40266437
68Ga-labeled prostate specific membrane antigen HBED-CC PET/MRI for staging and evaluating the clinicopathological characteristics in newly diagnosed prostate cancer., PMID:40259392
Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)., PMID:40246173
Optimization of synthesis conditions of [68Ga]Ga-PSMA-D5 and its clinical application in prostate cancer., PMID:40228351
Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer., PMID:40214467
Dual targeting PET tracer [68Ga]Ga-PSFA-01 in patients with prostate cancers: A pilot exploratory study., PMID:40213671
Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT., PMID:40210421
First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer., PMID:40204598
Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy., PMID:40187648
Using mpMRI, PSMA, and GRPR PET to Assess Focal Therapy Eligibility and Plan Treatment in Biopsy-proven Low-/Intermediate-risk Prostate Cancer: A Whole-mount Pathology-based Study., PMID:40179293
Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr., PMID:40176353
A small-molecule pretargeting approach for PSMA-targeted conjugates., PMID:40158638
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment., PMID:40155242
Exploring Si-phthalocyanines with different valency for PSMA-targeted photodynamic therapy: Synthesis and preclinical validation., PMID:40147340
Advances in PSMA-Targeted Radionuclide Therapeutics., PMID:40138150
Preclinical Evaluation of a Novel PSMA-Targeted Agent 68Ga-NOTA-GC-PSMA for Prostate Cancer Imaging., PMID:40137569
Development of [99mTc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer., PMID:40135799
Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study., PMID:40122284
Novel Application of Lutetium-177-Prostate Specific Membrane Antigen (LuPSMA) Radioligand Therapy for Metastatic Synovial Sarcoma., PMID:40116302
Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics., PMID:40113222
Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study., PMID:40113221
Increased N-glycosylation of PSMA by GnT-V enhances tumor malignancy through interacting with JAK2 and the subsequent STAT3-mediated transcriptional activation in prostate cancer., PMID:40112979
Evaluation of PSMA-Targeted TREN-CAM Conjugates for Targeted Imaging of Cancer with 68Ga(III) and 45Ti(IV)., PMID:40103324
[Indications for performing PSMA-PET-CT as part of prostate cancer diagnostics]., PMID:40101786
Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model., PMID:40098725
For research use only. Not for human or drug use.
